Pharma Industry News
Printable Version   Email to a friend

President's FY 2009 Budget Advances Food and Medical Product Safety, and the Safety of FDA-Regulated Imports

ROCKVILLE, Md., Feb. 4, 2008--The U.S. Food and Drug Administration, part of the U.S. Department of Health and Human Services, is requesting nearly $2.4 billion to protect and promote public health as part of the President's fiscal year (FY) 2009 budget—a 5.7 percent increase over the budget that the FDA received for the current fiscal year.

The FY 2009 request, which covers the period of Oct. 1, 2008 through Sept. 30, 2009, includes $1.77 billion in budget authority and $628 million in industry user fees.

The budget proposal includes strategic increases to strengthen food protection, modernize drug safety, speed approval of generic drugs, and improve the safety and review of medical devices. The request also includes funds to cover cost of living increases for FDA employees that perform the agency's scientific and highly specialized public health mission. These investments build on the increases that the FDA received for FY 2008 and will help ensure the safety of the food supply and accelerate the availability of new, safe, and innovative medical products.

"The FDA is committed to protecting and promoting the health of the American people," said Andrew C. von Eschenbach, M.D., Commissioner of Food and Drugs. "This budget enables us to continue development of the staff and programs necessary to safeguard the food we eat and improve the safety and development of drugs, vaccines, devices, and other medical products."

The FDA primarily delivers its public health mission through its highly trained professional workforce. During FY 2009, the FDA will experience a full-time equivalent staff increase of 526. The FY 2009 budget supports additional staff for priority areas such as food defense and food safety, and drug, blood, and human tissue safety programs. The FDA will also work to assure the safety of domestic and imported food and medical products by conducting more domestic and foreign inspections and more inspections of high risk foods.

The following are the FDA's key proposed budget increases:

Protecting America's Food Supply ($42.2 million)

The FDA's Protecting America's Food Supply initiative integrates food safety and food defense and uses a comprehensive, preventative, and risk-based approach to safeguard the food supply and the American homeland. The investment allows the FDA to implement components of the Administration's Food Protection Plan, Import Safety Action Plan, and December 2007 agreements with China.

The foundation of the FDA plan is to increase its focus on prevention, to identify potential food threats to the food supply and counteract them before they harm consumers. The FY 2009 increase will allow the agency to focus on the most important food defense and food safety issues throughout the entire life cycle of foods, from production through consumption. In FY 2009, the FDA will devote more workforce and resources to food production and handling sites, whether they are located in the United States or abroad.

Medical Product Safety and Development ($17.4 million, $79.0 million user fees)

This initiative provides targeted resources to improve the safety of human and animal drugs, blood, human tissues, and medical devices. The resources in this initiative will strengthen the FDA's ability to effectively monitor the safety of medical products, including imported products. The agency will also help medical product manufacturers develop new products to treat life-threatening diseases and conditions.

In 2007, Congress enacted the Food and Drug Administration Amendments Act (FDAAA). The FY 2009 budget implements new drug and medical device safety programs in FDAAA that are funded by user fees. As a result, the FDA will strengthen its ability to regulate medical products and assure the safety and effectiveness of these products for the American public.

Management Efficiencies

The FY 2009 budget also captures the productivity savings (-$8.9 million) generated by recent FDA investments and reinvests the savings in priority food safety and medical product programs.

For more information on the President's FY 2009 budget for the FDA, visit: http://www.fda.gov/oc/oms/ofm/budget/documentation.htm

#

Media Inquiries:
Christopher Kelly, 301-827-6242
Consumer Inquiries:
888-INFO-FDA

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


MedNotes
Latest FDA Drug Alerts
October 9, 2008
Audience: Pediatric and primary healthcare professionals, consumers [Posted 10/09/2008] FDA notified healthcare professionals and...
October 7, 2008
Audience: Pulmonary care health professionals and patients[UPDATE 10/07/2008] FDA informed healthcare professionals that FDA has...
October 3, 2008
Audience: Healthcare professionals, consumers [Posted 10/03/2008] FDA notified healthcare professionals of a Class I Recall of...
October 2, 2008
Audience: Physical medicine and rehabilitation specialists, anesthesia healthcare professionals, hospital surgical service...
More...
Latest Drug Information Updates

Cinryze
Cinryze is a C1-esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).

Akten
Akten (lidocaine hydrochloride) Ophthalmic Gel is a topical, ocular anesthetic formulation for use in ocular procedures that require a topical anesthetic agent.

AdreView
AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.

Sancuso
Sancuso (granisetron transdermal system) is an anti-emetic transdermal delivery system indicated for the control of nausea and vomiting in patients receiving moderately and/or highly nausea-inducing chemotherapy.

Nplate
Nplate (romiplostim) is a thrombopoietin mimetic peptibody for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Xenazine
Xenazine (tetrabenazine) is a selective and reversible centrally-acting dopamine depleting drug indicated for the treatment of chorea associated with Huntington's disease.

Cleviprex
Cleviprex is an intravenous, ultrashort-acting calcium channel blocker under development for the treatment of severely elevated blood pressure in the hospital setting when oral therapy is not feasible or desirable.

Stavzor
Stavzor is delayed-release valproic acid formulated in the EnteriCare enteric soft gelatin capsule delivery system designed to minimize GI adverse events. Stavzor is indicated for the treatment of manic episodes associated with bipolar disorder, adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.

Navstel
Navstel is a balanced salt ophthalmic solution for use as an intraocular irrigation during surgical procedures involving perfusion of the eye.

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

More...